An early analysis of a prospective PSMA-directed focal reirradiation for locally recurrent prostate cancer using 36 Gy in 6 fractions without the use of ADT has recently reported an estimated 80% bRFS rate at 2 years and a 4% late grade 2 GU toxicity (45). This evidence concerns the gene FOLH1 and prostate carcinoma.